Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04614467 · ClinicalTrials.gov registry record · Phase 2
A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction
A Phase 2 study, sponsored by Lisata Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT04614467: Clinical Trial Phase 2 study, sponsored by Lisata Therapeutics.
NCT04614467 is a Phase 2 study that was terminated before completion, run by Lisata Therapeutics. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04614467, a Phase 2 study, was terminated before completion, sponsored by Lisata Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This clinical trial will explore the efficacy and safety of GCSF-mobilized autologous CD34+ cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease. Eligible subjects will receive a single administration of CLBS16 or placebo.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL CLBS16
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2020-10-29 |
| Est. Completion | 2022-09-28 |
| Phase | Phase 2 |
Why NCT04614467 stopped before completion
NCT04614467 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04614467 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04614467 about?
NCT04614467 is a clinical study titled "A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction". This clinical trial will explore the efficacy and safety of GCSF-mobilized autologous CD34+ cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease. Eligible subjects will receive a single administration of CLBS16 or placebo.
What is the current status of trial NCT04614467?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2020-10-29. Estimated completion is 2022-09-28.
What interventions are being tested in trial NCT04614467?
The interventions under investigation include: Placebo (BIOLOGICAL), CLBS16 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04614467?
This trial is sponsored by Lisata Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04614467's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI